Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 12,470 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey purchased 12,470 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were acquired at an average cost of $19.80 per share, for a total transaction of $246,906.00. Following the completion of the transaction, the director directly owned 996,502 shares in the company, valued at approximately $19,730,739.60. This represents a 1.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Tim Kutzkey also recently made the following trade(s):

• On Wednesday, January 14th, Tim Kutzkey acquired 5,523 shares of Surrozen stock. The stock was bought at an average price of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 6th, Tim Kutzkey bought 15,100 shares of Surrozen stock. The stock was bought at an average cost of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Tim Kutzkey purchased 30,884 shares of Surrozen stock. The shares were bought at an average cost of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The shares were bought at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The stock was purchased at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Performance

Shares of SRZN opened at $20.00 on Friday. The company’s fifty day simple moving average is $18.54 and its 200 day simple moving average is $13.84. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94. The company has a market cap of $171.40 million, a price-to-earnings ratio of -0.90 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The firm had revenue of $0.98 million during the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. As a group, research analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

SRZN has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Finally, Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Woodline Partners LP acquired a new stake in shares of Surrozen during the third quarter worth $621,000. Millennium Management LLC acquired a new stake in Surrozen in the 3rd quarter worth about $1,414,000. Citadel Advisors LLC grew its position in shares of Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Surrozen during the third quarter worth approximately $889,000. Finally, Acuta Capital Partners LLC raised its position in shares of Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after buying an additional 8,415 shares in the last quarter. Institutional investors own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.